unknown by Milsted, R. et al.
Clinical trial design issues: Session 1
R. Milsted a, T. Hinz b, C.C. Zielinski c. a European Regulatory
Affairs, Celtic Pharma, Leverton House, 13 Bedford Square, London
WC1A 3RB, United Kingdom. b Head Section Therapeutic Vaccines,
Paul-Elrich-Institute, Paul-Elrich-Straße 51-59, D-63225 Langen,
Germany. c First Department of Medicine and Cancer Centre, Clinical
Division of Oncology, Medical University of Vienna, 18-20 Waehringer
Guertel, A-1090 Vienna, Austria
E-mail address: bob.milsted@dev.celticpharma.com (R. Milsted)
ABSTRACT: Anticancer therapeutic intervention in patients with
solid tumours still relies on the necessity of empirically treating
many patients to obtain benefit for a limited few. The activity of
a given drug in patients with advanced cancer is the result of a
pharmacodynamic interaction with a pathway. Such putative
pathways must be both prevalent in the cancer cells and relevant
to the process of uncontrolled cell proliferation. Several examples
have clearly demonstrated the value of measuring the molecular
target and using it as inclusion criteria for clinical trials. Adaptive
trial designs and the definition of clinical surrogate end-points
can be helpful tools to further improve clinical drug development.
In general go/no go decisions must be established prospectively.
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Anticancer therapeutic intervention in patients with solid
tumours still relies on the necessity of empirically treating many
patients to obtain benefit for a limited few. The activity of a given
drug in patients with advanced cancer is the result of a pharma-
codynamic interaction with a pathway. Such putative pathways
must be both prevalent in the cancer cells and relevant to the pro-
cess of uncontrolled cell proliferation.
Many molecularly targeted anticancer agents have demon-
strated limited effectiveness thus far. An example is the marginal
impact on overall survival of erlotinib (Tarceva), an epidermal
growth factor receptor inhibitor, after first- or second-line treat-
ment, compared to placebo. The respective study involved 731
patients with advanced non-small-cell lung cancer (NSCLC).1
After adjusting for stratification factors and epidermal growth
factor receptor (EGFR) status, the survival curves for the two treat-
ments started to diverge after 2 or 3 months. At 1 year, 31% of
patients treated with erlotinib were still alive, compared with
22% of those on placebo.
Similarly, new therapeutic schemes for treating hormone-
refractory prostate cancer have shown only limited effects on
overall survival. In one study involving 674 men, the median over-
all survival was 17.5 months in the group given docetaxel and est-
ramustine, and 15.6 months in those given mitoxantrone and
prednisone. The corresponding hazard ratio for death was 0.80.2
DESIGNING TRIALS: One way to streamline clinical trials of new
anticancer agents is to use biomarkers rather than clinical end-
points. Several examples of novel markers for assessing effective-
ness and predicting response to therapy were discussed.
Methylation-dependent transcriptional silencing of 14-3-3r, a
major G2-M checkpoint control gene, could be a new, indepen-
dent prognostic factor for survival in NSCLC patients receiving
platinum-based chemotherapy.3 14-3-3r methylation was
observed in all histologic types of 39 patients (34%). And median
survival was significantly longer in the methylation-positive
group (15.1 versus 9.8 months). Median time to progression was
8 months in the methylation-positive group and 6.3 months in
the methylation-negative group. Furthermore, 14-3-3r methyla-
tion might be a prognostic marker. The estimated survival rate
at 18 months was 64% amongst methylation-positive responders
and 21% amongst methylation-negative responders. Methylation-
negative responders had a fourfold greater risk of death during
follow-up than those who were methylation-positive. Addition-
ally, translational research studies in advanced NSCLC are limited
by a lack of tumour biopsy tissue, but methylation of 14-3-3r can
be reliably and conveniently detected in the serum, thus obviat-
ing the need for tumour tissue analysis in translational studies.
As another example trabectedin (Yondelis) induced long last-
ing responses and tumour control in a clinically relevant propor-
tion of sarcoma patients resistant or relapsed to conventional
chemotherapy.4 After the EMEA/CHPM positive opinion and
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